News
-
Tip Sheet: Johns Hopkins Researchers Present at Annual CROI Meeting
Date: 03/01/2018
Publication: Newswise
A5279 and P1078 are referenced in this press release from Johns Hopkins Medicine.
Access Full Press Release
World AIDS Day: BJGMC Team Offers Community Counseling and Preventive Care
Date: 12/21/2017
Publication: amfAR
Each year, World AIDS Day serves as time for important community outreach at the BJGMC Clinical Research Site. This year was no different.
On Friday, December 1, 150 people participated in a non-communicable diseases awareness camp for people living with HIV that was convened by the BJGMC-CRS Team at the Antiretroviral Therapy Center at Sassoon General Hospitals, Pune. Activities were led by Dr. Shashikala Sangle (Principal Investigator of TREAT Asia studies), Dr. Sandesh Patil (Clinical Coordinator at BJGMC-CRS), Mrs. Suhasini Surwase (TREAT Asia Counselor) and counselors Mrs. Archana Pawar and Mrs. Kanta Zarekar.
Discussions and activities were focused on the complications of having HIV and non-communicable disease, and the importance of identifying symptoms associated with non-communicable diseases and getting regular screenings to facilitate early diagnosis and prevent severe disease. Free blood sugar and blood pressure screenings were offered. Following biometric assessment, counselors spoke with attendees about the importance of maintaining a healthy lifestyle, including proper nutrition and exercise, while taking antiretroviral therapy. To incentivize healthy nutrition, attendees were provided with fruits at the end of their assessment.
The team developed a rolling presentation covering the essentials about non-communicable that was was played throughout the day. The BJGMC-CRS team would like to extend their gratitude to Dr. Sangle and all the ART center staff for helping to make this program successful!
IMPAACT 2001 (DAIDS ID 12026): Evaluating the Pharmacokinetics, Tolerability, and Safety of
Date: 03/06/2017
Publication: Once-Weekly Rifapentine and Isoniazid in HIV-1-Infected and HIV-1-Uninfected Pregnant and Postpartum Women With Latent...
OPEN TO ACCRUAL
IMPAACT 2001
V1.0 of IMPAACT 2001, a PK study of rifapentine and isoniazid in pregnant and postpartum women, has opened to accrual.
Read more on ACTG Network
CROI 2017 Highlighted ACTG Network Presentations
Date: 02/28/2017
Publication: ACTG Network
Kevin Robertson, PhD, Investigator, University of North Carolina, Chapel Hill Clinical Research Site
A5303 was entitled “Systemic Inflammatory and Immune Biomarkers in Neurocognitive Changes with Initial ART” and was the largest randomized clinical trial studying neurocognitive outcomes ever conducted in the United States with over 200 treatment naïve participants who were followed after ART initiation for 48 weeks. Within the HIV research community, considerable interest in neurocognitive impairment in HIV as well as the desire to better understand the underlying pathogenesis of HIV-associated neurocognitive disorder (HAND). Biomarkers are an important way of looking at that pathogenesis to try to understand how HAND develops, and why it continues in some on effective antiretroviral therapy.
A5303 researchers found correlations between activated T cells and neurocognitive performance at baseline when viral loads are high, but these correlations were not there after the virus was suppressed with treatment. However, after the virus was suppressed, there were correlations between monocytes and neurocognitive impairment, not there at baseline. This finding fits some theories of which cells (monocytes) are driving HAND. These findings suggest that the driving mechanism behind HAND before ART and on ART may be different. In large part, A5303 confirmed that biomarkers in the periphery, (the blood) provided only weak correlations with neurocognitive impairment, and are likely too distant from the brain to be predictive. Biomarkers from Cerebrospinal Fluid (CSF) are likely more reflective of processes in the brain and central nervous system.
A5303 established that only a few biomarkers sampled in the blood were related to neurocognitive impairment. There is still a need to better understand the pathogenesis underlying continued neurocognitive impairment, and to continue looking for the causes to be able to better treat and prevent HAND.
Read more on ACTG Network
The Success of HIV Treatment Is Increasing the Risk of Drug-Resistance
Date: 12/07/2016
Publication: Huffington Post
Global health agencies are succeeding in getting more people with HIV on antiretroviral therapy, a combination of drugs that suppress the virus to undetectable levels in the blood and reduce the risk of transmission to another person. But scientists are beginning to detect a disturbing new trend: The rise of drug-resistant HIV strains, especially in countries such as Kenya, Zambia, Uganda, Nigeria, Tanzania and South Africa. Read more on Huffington Post website
BWI-CTU Researchers Elected to ACTG Network Committees
Date: 11/30/2016
Publication:
November 29, 2016—The ACTG Network announced today the results of elections for the network's laboratory, leadership, science, and resource committees. Congratulations to the following BWI-CTU researchers, who were elected to serve for the term of December 1, 2016 – November 30, 2017:
Christine Durand, Johns Hopkins Clincial Trials Site (Baltimore) Investigator, HIV Reservoirs & Viral Eradication Transformative Science Group. David Hardy, Whitman-Walker Clincial Trials Site (Washington) Investigator, HIV Reservoirs & Viral Eradication Transformative Science Group. Ya-Chi Ho, Johns Hopkins Clincial Trials Site (Baltimore) Investigator, HIV Reservoirs & Viral Eradication Transformative Science Group. Charles Flexner, Johns Hopkins Clincial Trials Site (Baltimore) Non-voting Member, Antiretroviral Therapy Strategies Subcommittee. Vidya Mave, Byramjee Jeejeebhoy Clincial Trials Site (India) Investigator, Tuberculosis Transformative Science Group. Eric Nuermberger, Johns Hopkins Clincial Trials Site (Baltimore) Investigator, Tuberculosis Transformative Science Group. Ilene Wiggins, Johns Hopkins Clincial Trials Site (Baltimore) Chair, Site Management & Clinical Care CommitteeACTG Network Monthly Newsletter - August 2016
Date: 08/30/2016
Publication: ACTG
Women's Outreach Workers Project Releases New Educational Video
New Video Addresses Questions Women and Minorities May Have Regarding ACTG Network Clinical Trials
The Women's Outreach Workers (WOW) Project was established with the goal of developing optimal strategies for increasing recruitment and retention of women, particularly women of color in ACTG Network clinical trials. Led by Susan E. Cohn, MD, MPH, Investigator at our Northwestern University Site, and working in collaboration with the Women's Health Inter-Network Scientific Committee (WHISC) and the Underrepresented Populations Committee (UPC), the WOW Project team created an educational video to help to answer many questions women and minorities may have about participating in ACTG Network clinical trials.
Click HERE for the rest of the article and to view the video.
Dr. Anne Rompalo to Receive 2016 Distinguished Career Award of the American STD Association
Date: 05/03/2016
Publication:
Dr. Anne Rompalo will be awarded the 2016 Distinguished Career Award of the American STD (Sexually Transmitted Diseases) Association. This award is presented annually to recognize a career of accomplishment in research, service and teaching in sexually transmitted infections. Dr. Rompalo’s career in STDs began during her fellowship in the early 1980s at the University of Washington, and she has been a faculty member at Hopkins since 1988. She is internationally known for her work in describing the gay bowel syndrome (proctitis enteritis), and her clinical research on syphilis and genital ulcer diseases, the relationship between STDs and HIV, and HIV prevention. She has been the PI of the CDC funded Baltimore HIV/STD Prevention Center since 1992, and is well known for her teaching enthusiasm. The award will be presented in September at the 2016 STD Prevention Conference in Atlanta, Georgia.
The daily pill regiment “PrEP” works to rid HIV negative
Date: 04/01/2016
Publication: WJLA - Good Morning Washington
Whitman Walker Health’s Megan Coleman appeared on Good Morning Washington on Thursday, March 31, 2016 to talk about HIV Pre-Exposure Prophylaxis (PrEP)
Click HERE or on the photo to view the video.
Feasibility Study Complete on Preventive Therapy for Household Contacts of
Date: 03/31/2016
Publication: Published by BWI-CTU
March 31, 2016—Pune, India—The Baltimore-Washington-India Clinical Trials Unit is pleased to announce that the BJGMC Clinical Research Site (BJGMC-CRS) in Pune, India, just finished the feasibility study titled A5300/IMPAACT2003: Study of MDR-TB Cases and their Household Contacts: Operational Feasibility to Inform PHOENIx Trial Design.
Funded by the National Institute of Allergy and Infectious Diseases at the National Institutes of Health, the feasibility study was successfully completed with support from the Revised National Tuberculosis Control Programme (RNTCP), Pune, India. The BJGMC-CRS had the second highest participant enrollment among all study sites during the feasibility phase.
The main study is a large, 8-year, multi-country trial that will be conducted on 5 continents to determine the efficacy of a new drug to prevent development of TB among the household contacts of TB patients. WHO currently has no guidelines for TB prevention for people living with TB patients. Specifically, the main study will compare whether preventive treatment with delamanid substantially reduces the risk of developing TB versus treatment with isoniazid preventive therapy in child, adolescent, and adult household contacts of MDR-TB patients.
BJGMC-CRS Community Advisory Board (CAB) met in Pune, India, March 18, 2016, to conclude the feasibility phase of the trial. Savita Kanade (Community Coordinator and CAB liaison, BJGMC-CRS) and Dr. Nishi Suryavanshi (BJGMC-CRS Coordinator) and Prasanna Sahoo (Outreach Coordinator, BJGMC-CRS) concluded the study update and acknowledged the support of RNTCP, specifically honoring the contributions of Mr. Sachin Patil (PCMC), Mr. Bharat Gundal (PMC) and Ms. Pratima Vanjari (Rural). Geeta Pardeshi (PMC) accepted the honor on behalf of Pratima Vanjari, who was unable to attend.
- ‹ First < 2 3 4 5 >